Compare Davita Inc (DVA) vs e l f Beauty Inc (ELF) Price & Performance

DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.

Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.

ELF Beauty trades at $109.12, up 3.89% today, and is near its R3 resistance level of $109. The stock shows strong technical momentum with bullish moving averages, though RSI levels above 70 indicate potential overbought conditions. Fundamentally, the company reported revenue of $1.31 billion in 2025 with a net income of $112.09 million, and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength. Expansion into Europe via Sephora for the rhode brand and marketing initiatives like the 'Mirror Mix' album signal aggressive growth strategies.

The outlook for ELF is positive given earnings momentum and international expansion, but the high P/E ratio of 108.12 poses valuation risks. Analyst consensus is a 'Buy' with a price target of $95.91, below the current price, suggesting limited near-term upside. Key risks include competitive pressures in the beauty sector and sensitivity to consumer spending trends. Institutional buying activity, such as State Street Corp's increased stake, supports confidence in long-term growth.